Pérez VG, Díaz MV

Language: Spanish
References: 9
Page: 247-249
PDF size: 141.02 Kb.

ABSTRACT

Molluscum contagiosum (MC) is an infection caused by a poxvirus. It is benign and self-limiting. In immunosuppressed patients, there are atypical presentations with larger and disseminated lesions. Fingolimod was the first oral drug, approved by the Food and Drug Administration (FDA) for multiple sclerosis, causing immunosuppression and increasing a susceptibility to viral infections. We present a 49-year-old female patient with a history of multiple sclerosis being treated with fingolimod for two years who presents disseminated molluscum contagiosum.

REFERENCES

1. Hebert A, Bhatia N y Del Rosso J, Molluscum contagiosum: epidemiology,considerations, treatment options, and therapeuticgaps, J Clin Aesthet Dermatol 2023; 16:4-11.

2. Murali S, Bhat P, Prathiba J y Jithendriya M, Disseminated molluscumcontagiosum presenting during fingolimod treatment ina child, Int J Dermatol 2024; 63(6):816-7.

3. Pelletier D y Hafler D, Fingolimod for multiple sclerosis, N EnglJ Med 2012; 4:339-47.

4. Beutler B y Cohen P, Molluscum contagiosum of the eyelid:case report in a man receiving methotrexate and literature reviewof molluscum contagiosum in patients who are immunosuppressedsecondary to methotrexate or hiv infection, DermatolOnline J 2016; 22:3.

5. Schneider S, Fuller R y Berger J, Molluscum contagiosum in thesetting of fingolimod: the experience at one institution, MultScler Relat Disord 2022; 58:103419.

6. Behle V, Wobser M, Goebeler M y Stoevesandt J, Extensivemolluscum contagiosum virus infection in a young adult receivingfingolimod, Mult Scler 2016; 22:969-71.

7. Triplett J, Kermode A, Corbett A y Reddel S, Warts and all: fingolimodand unusual hpv-associated lesions, Mult Scler 2019;25:1547-50.

8. Nitsan Z, Kucuk N, Appel S, Tichmanovich N, Osherov M y MiloR, Mycosis fungoides: a cutaneous lymphoproliferative disorderin a patient treated with fingolimod for multiple sclerosis, J ClinNeurosci 2018; 48:102-3.

9. García E, Berna E, De Nicolás B, Azcárraga C, Alonso L y BeaS, Imiquimod as local immunotherapy in the management ofpremalignant cutaneous conditions and skin cancer, Int J MolSci 2023; 24:10835.